




- (51) **International Patent Classification:**
C07K 14/55 (2006.01) C07K 19/00 (2006.01)
- (21) **International Application Number:**
PCT/US2021/055877
- (22) **International Filing Date:**
20 October 2021 (20.10.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/104,376 22 October 2020 (22.10.2020) US
63/181,075 28 April 2021 (28.04.2021) US
- (71) **Applicant:** GILEAD SCIENCES, INC. [US/US]; 333 Lakeside Drive, Foster City, California 94404 (US).
- (72) **Inventors:** BACA, Manuel; 12 Coolidge Avenue, Lexington, Massachusetts 02420 (US). GILMORE, Sarah A.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). HUNG, Magdeleine S.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). JAVANBAKHT, Hassan; 340 Fremont Street, Apt. 2910, San Francisco, California 94105 (US).

KANWAR, Manu; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). KHAN, Shahzada; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). MUKHERJEE, Prasenjit K.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). NAGEL, Mark R.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). PAPALIA, Giuseppe; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). TAM, Danny W.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). THOMAS, Majlinda K.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

- (74) **Agent:** WAHLSTEN, Jennifer L. et al.; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

- (54) **Title:** INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE



- (57) **Abstract:** Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2R α (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*